What is the clinical evidence from this study?

Study design: Other. Population: Fetal supraventricular tachycardia (SVT) and atrial flutter (AFL) (n=50). Intervention: Transplacental treatment using digoxin, sotalol, and flecainide. Primary outcome: Resolution of fetal tachyarrhythmia.

What does this research mean for the field?

Protocol-defined transplacental treatment with digoxin, sotalol, and flecainide resolves fetal supraventricular tachycardia and atrial flutter in approximately 90% of cases, though it carries risks of serious fetal adverse events and neonatal recurrence. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy, safety, and therapeutic protocols of transplacental antiarrhythmic pharmacotherapy in treating fetal supraventricular tachyarrhythmias.

September 7, 2026Journal of the American College of CardiologyOpen Access

Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias

View Full Paper

Ask AI

Bookmark

Key result

Protocol-defined transplacental treatment with digoxin, sotalol, and flecainide resolves ~90% of fetal tachyarrhythmias.

n=50

Why the study?

Standardized treatment of fetal tachyarrhythmia has not been established.

Population

50 singleton pregnancies from 22 to <37 weeks of gestation with sustained fetal SVT or AFL >=180 beats/min

Comparison

Protocol-defined transplacental treatment using digoxin, sotalol, and flecainide

Design

Multicenter, single-arm trial

Authors

TMTakekazu MiyoshiNational Cerebral and Cardiovascular Center YMYasuki MaenoSt Mary's Hospital THToshimitsu HamasakiMilken Institute

Discussion

Member takes

Implication

Clinical review evaluates transplacental antiarrhythmic treatments for fetal tachycardia, indicating high conversion rates to normal sinus rhythm.

Key Points

To evaluate the efficacy, safety, and therapeutic protocols of transplacental antiarrhythmic pharmacotherapy in treating fetal supraventricular tachyarrhythmias.
Reviewed clinical outcomes of transplacental drug administration in fetuses diagnosed with sustained supraventricular tachycardia or atrial flutter.
Evaluated first-line and combination medical regimens, including maternal administration of digoxin, flecainide, and sotalol, across hydropic and non-hydropic fetuses.
Transplacental antiarrhythmic pharmacotherapy successfully converts fetal supraventricular tachyarrhythmias to normal sinus rhythm in the majority of affected fetuses.
Non-hydropic fetuses exhibit significantly higher and more rapid cardioversion rates compared to hydropic fetuses requiring multi-drug escalation.

PICO

Population

50 singleton pregnancies from 22 to <37 weeks of gestation with sustained fetal SVT or AFL ≥180 beats/min treated with transplacental therapy.

Intervention / Comparator

Transplacental treatment using digoxin, sotalol, and flecainide

Primary Outcome

Resolution of fetal tachyarrhythmia

Limitations

Serious adverse events may take place in fetuses
Tachyarrhythmias may recur within the first 2 weeks after birth

Cite This Study

Miyoshi et al. (2019) studied Fetal supraventricular tachycardia (SVT) and atrial flutter (AFL) (n=50). Transplacental treatment using digoxin, sotalol, and flecainide was evaluated on Resolution of fetal tachyarrhythmia. Protocol-defined transplacental treatment using digoxin, sotalol, and flecainide resolved fetal tachyarrhythmia in 89.8% of cases.

synapsesocial.com/papers/6a9ed5daae051fe680bc566a https://doi.org/10.1016/j.jacc.2019.06.024

View Full Paper

Ask AI

Bookmark

Implication

Clinical review evaluates transplacental antiarrhythmic treatments for fetal tachycardia, indicating high conversion rates to normal sinus rhythm.

Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias

Discussion

Member takes

Implication

Key Points

PICO

Limitations

Cite This Study

Also Consider

Also Consider